Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse - Full Text View

Purpose

Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.

Condition	Intervention
Schizophrenia Cannabis Dependence, Continuous	Behavioral: Motivational therapy Behavioral: Usual care


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	An Open Multicentric Randomized Clinical Trial Assessing the Impact of Motivational Interviewing on Cannabis Consumption in Patients With Psychiatric Disease

Resource links provided by NLM:

Genetics Home Reference related topics: schizophrenia

MedlinePlus related topics: Marijuana Schizophrenia

U.S. FDA Resources

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:

Cannabis consumption evaluated by the Time-Line Follow Back at 6 months with mean percentage of abstinent day [ Time Frame: inclusion, 3 month, 6 month, 12 month ]

Secondary Outcome Measures:

PANSS, GAF, number of DSM-IV criteria of cannabis dependence, May scale for treatment response, SF-12, la URICA, number of hospitalisation, mean number of joints per week, D9THC urinanalysis at 6M and cannabis consumption evaluated by the TLFB at 6M [ Time Frame: inclusion, 3 month, 6 month, 12 month. Only inclusion and 6 month for urianalysis ]
PANSS : global, positive, negative, general scores


Enrollment:	97
Study Start Date:	November 2008
Study Completion Date:	April 2013
Primary Completion Date:	October 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Motivational Therapy Four motivational interview for cannabis abuse in schizophrenia population during one month	Behavioral: Motivational therapy One hour of motivational therapy each weak during 4 weeks
Usual Care Usual care with intensive psychotherapy	Behavioral: Usual care Patients received at least six hour of usual therapy, as in the experimental group

Detailed Description:

Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.

330 patients with schizophrenia and cannabis abuse or dependence (according to DSM-IV criteria) are randomly assigned to 4 motivational interview during one month or usual intensive treatment. Treatment is conducted in outpatient which are evaluated at the inclusion and at 6 month with Time-Line Follow Bach for the consumption, PANSS score, number of relapse…). A outcome measure was urinalysis results providing an objective measure of cannabis use throughout the six month of the trial.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA:

Schizophrenia or schizo-affective disorder according to DSM-IV criteria
Meeting DSM-IV criteria for actual cannabis abuse or dependance
in current and regular contact with mental health service
with an age at interview of 18 years or more
No evidence of organic brain disease or clinically significant concurrent medical illness or learning disability
Written informed consent was obtained from all subjects (patients and parents).

EXCLUSION CRITERIA:

Not membership to a regime of social security or to a CMU

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00798109

Locations


France
Service de psychiatrie (Pr Adès)
Colombes, France, 92700

Sponsors and Collaborators

Assistance Publique - Hôpitaux de Paris

Investigators


Principal Investigator:	Caroline DUBERTRET, MD,PhD	Assistance Publique - Hôpitaux de Paris

More Information


Responsible Party:	Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:	NCT00798109 History of Changes
Other Study ID Numbers:	P 070156 AOM 07007 ( Other Identifier: French Ministry )
Study First Received:	September 30, 2008
Last Updated:	June 13, 2014

Keywords provided by Assistance Publique - Hôpitaux de Paris:


Schizophrenia Cannabis misuse comorbidity Motivational interview Randomised open trial

Additional relevant MeSH terms:


Schizophrenia Marijuana Abuse Substance-Related Disorders	Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Chemically-Induced Disorders

ClinicalTrials.gov processed this record on June 26, 2017

Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse (SCHIZOCAN)